What do brand-name GLP-1 medications cost at the pharmacy counter?
Brand-name GLP-1 medications carry list prices between $935 and $1,350 per month for a cash-paying patient in 2026, depending on the drug and dose. Wegovy (semaglutide 2.4 mg injection), which is FDA-approved for chronic weight management, carries a list price of approximately $1,350 per month. Zepbound (tirzepatide injection), also FDA-approved for weight management, lists at roughly $1,086 per month, according to Eli Lilly's published pricing.
Ozempic (semaglutide) and Mounjaro (tirzepatide) are their respective manufacturers' diabetes-indicated formulations. Both are FDA-approved for type 2 diabetes only and are not approved by the FDA for obesity or weight management. Ozempic's list price is roughly $935 to $1,000 per month. Mounjaro's is approximately $1,112 per month following a price adjustment in early 2026, according to GoodRx pricing data. Clinicians who prescribe a GLP-1 specifically for weight management generally write for Wegovy or Zepbound because those are the FDA-approved weight-management formulations.
Because all four medications are protected by active patents, no FDA-approved generic versions exist for any of them. The list price is the wholesale acquisition cost and is the baseline from which all other prices are calculated. The sections below cover every realistic path to a lower cost: manufacturer direct programs, commercial insurance, savings cards, and compounded alternatives.
What manufacturer self-pay programs exist, and how much do they cost?
Both Novo Nordisk and Eli Lilly run direct self-pay programs that substantially reduce costs for patients paying without insurance. Through NovoCare Pharmacy, new patients can access Wegovy (semaglutide) pen injections at $199 per month for the first two fills, a limited offer running through December 31, 2026. After that introductory window, standard maintenance doses (0.25 mg through 2.4 mg) cost $349 per month. Wegovy is also available in a daily oral tablet form; NovoCare prices the 1.5 mg and 4 mg tablet doses at $149 per month, with a 4 mg introductory price available through August 31, 2026.
Eli Lilly's direct self-pay program offers Zepbound (tirzepatide) as single-dose vials at $299 for the 2.5 mg dose, $399 for the 5 mg dose, and $449 per month for higher maintenance doses, following a price reduction Lilly announced in late 2025. Patients at higher dose levels must refill within 45 days to maintain the self-pay price.
GoodRx has also formed a manufacturer-backed pricing arrangement with Novo Nordisk that makes Ozempic available at $199 per month for eligible self-paying patients through December 31, 2026, mirroring the NovoCare structure. That price applies to the diabetes-indicated drug only. None of these programs can be combined with Medicare or Medicaid benefits. Patients should confirm specific eligibility terms directly with each program before enrolling, as conditions and expiration dates apply.
Does commercial insurance cover GLP-1 medications for weight loss?
Commercial insurance coverage for GLP-1 medications prescribed for obesity is inconsistent and often denied outright. Ozempic, when prescribed for type 2 diabetes, is covered by approximately 85% of commercial plans. Wegovy, prescribed for the obesity indication, is covered by only about 45% of commercial plans, according to GoodRx's insurance coverage research. The gap exists because many employer benefit plans explicitly exclude weight-management medications as a category.
The coverage challenge does not end with plan enrollment. Of patients who do have coverage for a GLP-1 prescribed for weight management, the majority must still meet additional requirements before a claim will be processed, including prior authorization. Prior authorization typically requires documentation of a body mass index (BMI) of 30 or higher (or 27 or higher with a qualifying comorbidity such as hypertension or prediabetes), evidence of prior unsuccessful lifestyle interventions, and sometimes a letter of medical necessity from the prescribing clinician, as detailed by Healthline.
Patients whose insurance denies a GLP-1 claim have the right to appeal the decision. Submitting a formal appeal that includes comorbidity documentation and a letter of medical necessity from the prescribing provider strengthens the case. A second-level appeal to the plan's clinical review board is available if the first-level appeal fails. Coverage decisions should never be treated as final without attempting an appeal, particularly when comorbidities are present and documented.
What do Medicare and Medicaid cover for GLP-1s in 2026?
Since July 1, 2026, Medicare's GLP-1 Bridge Program gives eligible Part D enrollees a $50 per-month copay for FDA-approved weight-management GLP-1 medications, running through the end of 2027. Phase 1 eligibility (starting in 2026) requires a BMI of 27 or above combined with at least one qualifying comorbidity: cardiovascular disease, prediabetes, or hypertension. Phase 2, starting January 2027, is expected to expand to patients with a BMI of 30 or above without additional comorbidity requirements, according to KFF's analysis of Medicare GLP-1 coverage proposals.
Medicaid coverage remains limited. As of mid-2026, a minority of state Medicaid programs cover GLP-1 medications for the weight-loss indication. Budget pressure is the primary driver of limited coverage. Dual-eligible patients (enrolled in both Medicare and Medicaid) should verify with their specific plan how benefits coordinate.
One frequent point of confusion: manufacturer savings cards from Novo Nordisk and Eli Lilly cannot be used by Medicare beneficiaries. Federal law prohibits using those cards alongside a federal benefit program. The GLP-1 Bridge Program copay structure is the main pathway for reducing cost in that population, and patients should confirm with their Part D plan that their specific medication is included before assuming the $50 copay applies.
Do GoodRx and pharmacy discount cards lower GLP-1 costs meaningfully?
Standard third-party discount cards offer only limited savings on brand-name GLP-1 medications. Eli Lilly and Novo Nordisk structure their pharmacy contracts in ways that restrict what traditional coupon programs can offer. GoodRx coupons for Mounjaro typically show prices of $1,060 to $1,090 per month in 2026, compared to the list price of roughly $1,112, a savings of $20 to $50 per month at most, according to GoodRx's current Mounjaro pricing.
A meaningful exception: GoodRx has formed a manufacturer-backed pricing arrangement with Novo Nordisk that makes the diabetes drug Ozempic available to self-paying patients at $199 per month introductory pricing through December 31, 2026 (with ongoing prices of $349 to $499 after that window). This is essentially the NovoCare program made accessible through the GoodRx platform, and it covers the diabetes-indicated drug. It is not available for Wegovy (the weight-management-indicated version).
For cash-paying patients seeking a brand-name GLP-1 specifically for weight management, the most reliable path to below-list pricing runs through the manufacturer's own programs (NovoCare for Wegovy, LillyDirect for Zepbound) rather than standard coupon aggregators. Insured patients should also note that using a third-party discount card and insurance simultaneously is not permitted; the two savings approaches are mutually exclusive.
Why do compounded GLP-1s cost less, and how are they different from brand-name drugs?
Compounded semaglutide and tirzepatide typically cost $86 to $499 per month through telehealth providers. The price difference from brand-name medications reflects fundamental differences in regulatory status and manufacturing, not simply a better deal on the same product.
Compounded medications are individually prepared by a licensed compounding pharmacy for a specific patient under a valid prescription. The two categories of compounding pharmacy are FDA-registered 503B outsourcing facilities, which operate under federal Current Good Manufacturing Practice (CGMP) standards, and state-licensed 503A pharmacies, which are regulated at the state level. Neither category produces FDA-approved drugs. As the FDA has stated publicly, compounded medications are not reviewed for safety, efficacy, or quality before dispensing. Compounded semaglutide and tirzepatide have not been evaluated in clinical trials comparable to those conducted on Wegovy, Ozempic, Zepbound, or Mounjaro.
The lower cost reflects these structural differences: compounding pharmacies do not incur clinical trial expenses, patent royalties, or pharmaceutical-scale manufacturing and marketing costs. That reduces price, but it also means the compounded product carries a different regulatory history and quality-assurance profile than the approved drugs. For a detailed look at what that means for patients, see whether compounded semaglutide is safe.
Between September 2025 and June 2026, the FDA issued more than 110 warning letters to telehealth companies and compounders for misleading claims about compounded GLP-1 products, including language that implied equivalence to approved brand-name drugs or suggested that compounding facilities carried FDA approval. A provider using terms such as "generic Ozempic" or "same as Wegovy" for a compounded product is using language the FDA has explicitly prohibited.
GLP-1 cost ranges at a glance: a comparison by source and route
The table below summarizes typical monthly cost ranges for GLP-1 medications in 2026 by source. Actual costs depend on dose, insurance status, program eligibility, and individual pharmacy. List prices reflect publicly published wholesale acquisition costs. Self-pay and program prices are subject to change and eligibility requirements; verify current terms directly with the relevant program.
| Drug or Source | Typical Monthly Cost | Key Notes |
|---|---|---|
| Wegovy (semaglutide) - list price | ~$1,350 | FDA-approved for weight management; pen injection; no generic available |
| Wegovy - NovoCare self-pay, pen (new patient intro) | $199 | First 2 fills only, through Dec 31, 2026; then $349/mo for standard doses |
| Wegovy - NovoCare self-pay, pen (maintenance) | $349 | Standard doses (0.25 mg to 2.4 mg); $399/mo for the 7.2 mg HD dose |
| Wegovy - NovoCare self-pay, oral tablet | $149 | Daily tablet; 1.5 mg and 4 mg doses; 4 mg offer ends Aug 31, 2026 |
| Zepbound (tirzepatide) - list price | ~$1,086 | FDA-approved for weight management; pen injection; no generic available |
| Zepbound - LillyDirect vials (self-pay) | $299-$449 | Depends on dose; valid prescription required; 45-day refill condition at higher doses |
| Ozempic (semaglutide) - list price | ~$935-$1,000 | FDA-approved for type 2 diabetes only; not approved for weight management |
| Mounjaro (tirzepatide) - list price | ~$1,112 | FDA-approved for type 2 diabetes only; not approved for weight management |
| Compounded semaglutide (telehealth) | $86-$499 | Not FDA-approved; prepared at licensed compounding pharmacy; varies by provider and dose |
| Compounded tirzepatide (telehealth) | $120-$449 | Not FDA-approved; prepared at licensed compounding pharmacy; varies by provider and dose |
| Medicare GLP-1 Bridge Program copay (eligible patients) | $50 | In effect since July 1, 2026; Phase 1 requires BMI 27+ with qualifying comorbidity; covers approved brands only; confirm eligibility with your Part D plan |
What should an all-inclusive telehealth GLP-1 price actually cover?
A transparent telehealth GLP-1 subscription price should cover three things for the stated monthly amount: the medication itself, the provider evaluation (both initial and follow-up visits), and shipping. When any of those are billed separately, the advertised headline price does not reflect what a patient actually pays. The FTC's 2025 enforcement action against NextMed established a clear standard: the company had advertised GLP-1 program prices of $138 to $188 per month without disclosing that the drug cost, required lab work, and clinician consultations were billed on top of that amount. The settlement and final order, issued in December 2025, banned those practices and resulted in a $150,000 civil penalty.
When evaluating a telehealth program, ask in writing whether the following are included in the advertised price: the compounded medication or prescription fulfillment; the initial provider evaluation and any required follow-up appointments; lab work such as metabolic panels or lipid panels that some programs require before prescribing; and standard shipping. Auto-renewal terms must also be disclosed clearly before any billing information is collected; programs requiring a minimum one-year commitment with early termination fees must state that before enrollment, not after payment.
Telehealth programs that offer compounded GLP-1 medications vary widely in what is included at each price tier. Nuv (getnuv.com) offers compounded semaglutide starting at $149 per month as a first-order introductory price, with standard ongoing plan pricing published at getnuv.com; the price covers provider evaluation, medication, and standard shipping. Nuv's compounded semaglutide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or quality. It is available only by prescription after evaluation and approval by a licensed healthcare provider.
What questions should you ask before committing to any GLP-1 subscription?
Before enrolling in any GLP-1 program, whether through a traditional pharmacy or a telehealth provider, specific questions help prevent unexpected charges and allow accurate comparison across programs. Clinicians can also help patients evaluate whether a given program's product and approach are appropriate for their individual health situation.
- Is the quoted price all-inclusive? Confirm in writing that medication, provider visits, and shipping are all covered. Ask specifically whether lab work is included or billed separately.
- What drug am I receiving, and who prepares or dispenses it? Brand-name drugs (Wegovy, Zepbound) should come from a licensed retail pharmacy. Compounded medications should identify the specific 503A or 503B pharmacy by name. A provider that declines to name the pharmacy is a red flag.
- Is there a minimum commitment period or early termination fee? Month-to-month programs exist. A one-year commitment must be disclosed before payment, not buried in fine print at checkout.
- What happens if the provider declines the prescription? Responsible programs do not charge a patient until a licensed provider has reviewed and approved the prescription. Confirm whether a full refund applies if the evaluation results in a denial.
- Are follow-up visits and dose-titration consultations included? GLP-1 dosing typically starts low and increases over several months. Those titration check-ins require provider involvement. Confirm they are bundled into the stated price.
- How is medication shipped, and what happens to temperature-sensitive products in transit? Injectable GLP-1 medications require cold-chain handling. Understand what happens if a shipment is delayed or arrives outside the required temperature range.
No program can guarantee specific weight-loss results. A provider that promises a defined number of pounds lost, claims results are typical without providing data from their specific patient population, or implies their compounded product produces the same outcomes as an FDA-approved medication is making claims that regulators have consistently flagged. Any clinically important questions about whether a GLP-1 medication is appropriate for a specific patient should be directed to a licensed healthcare provider.